Bone Metastases: Mechanisms of the Metastatic Process, Imaging and Therapy

Hiraga, 2019, Bone metastasis: Interaction between cancer cells and bone microenvironment, J Oral Biosci, 61, 95, 10.1016/j.job.2019.02.002 Morgan-Parkes, 1995, Metastases: Mechanisms, pathways, and cascades, AJR Am J Roentgenol, 164, 1075, 10.2214/ajr.164.5.7717206 Hamaoka, 2004, Bone imaging in metastatic breast cancer, J Clin Oncol, 22, 2942, 10.1200/JCO.2004.08.181 Hamaoka, 2010, Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer, Br J Cancer, 102, 651, 10.1038/sj.bjc.6605546 Coleman, 2006, Clinical features of metastatic bone disease and risk of skeletal morbidity, Clin Cancer Res, 12, 6243s, 10.1158/1078-0432.CCR-06-0931 Langer, 2010, Skeletal morbidity in lung cancer patients with bone metastases: Demonstrating the need for early diagnosis and treatment with bisphosphonates, Lung Cancer, 67, 4, 10.1016/j.lungcan.2009.08.020 Geiger, 2009, Metastasis mechanisms, Biochim Biophys Acta, 1796, 293 Ardran, 1951, Bone destruction not demonstrable by radiography, Br J Radiol, 24, 107, 10.1259/0007-1285-24-278-107 Edelstyn, 1967, The radiological demonstration of osseous metastases. Experimental observations, Clin Radiol, 18, 158, 10.1016/S0009-9260(67)80010-2 Hortobagyi, 1984, Osseous metastases of breast cancer. Clinical, biochemical, radiographic, and scintigraphic evaluation of response to therapy, Cancer, 53, 577, 10.1002/1097-0142(19840201)53:3<577::AID-CNCR2820530335>3.0.CO;2-U Tehranzadeh, 1989, Comparison of CT and MR imaging in musculoskeletal neoplasms, J Comput Assist Tomogr, 13, 466, 10.1097/00004728-198905000-00019 Zimmer, 1985, Bone tumors: Magnetic resonance imaging versus computed tomography, Radiology, 155, 709, 10.1148/radiology.155.3.4001374 Costelloe, 2013, Bone windows for distinguishing malignant from benign primary bone tumors on FDG PET/CT, J Cancer, 4, 524, 10.7150/jca.6259 Costelloe, 2009, Imaging bone metastases in breast cancer: Techniques and recommendations for diagnosis, Lancet Oncol, 10, 606, 10.1016/S1470-2045(09)70088-9 Arano, 2002, Recent advances in 99mTc radiopharmaceuticals, Ann Nucl Med, 16, 79, 10.1007/BF02993710 Roodman, 2004, Pathogenesis of myeloma bone disease, Blood Cells Mol Dis, 32, 290, 10.1016/j.bcmd.2004.01.001 Daffner, 1986, MRI in the detection of malignant infiltration of bone marrow, AJR Am J Roentgenol, 146, 353, 10.2214/ajr.146.2.353 Roodman, 2008, Skeletal imaging and management of bone disease, Hematol Am Soc Hematol Educ Program, 313, 10.1182/asheducation-2008.1.313 Han, 1998, Comparison of bone single-photon emission tomography and planar imaging in the detection of vertebral metastases in patients with back pain, Eur J Nucl Med, 25, 635, 10.1007/s002590050266 Sedonja, 1999, The benefit of SPECT when added to planar scintigraphy in patients with bone metastases in the spine, Clin Nucl Med, 24, 407, 10.1097/00003072-199906000-00006 Horger, 2006, The role of single-photon emission computed tomography/computed tomography in benign and malignant bone disease, Semin Nucl Med, 36, 286, 10.1053/j.semnuclmed.2006.05.001 Corcoran, 1976, Solitary abnormalities in bone scans of patients with extraosseous malignancies, Radiology, 121, 663, 10.1148/121.3.663 Romer, 2006, SPECT-guided CT for evaluating foci of increased bone metabolism classified as indeterminate on SPECT in cancer patients, J Nucl Med, 47, 1102 Coleman, 1988, Bone scan flare predicts successful systemic therapy for bone metastases, J Nucl Med, 29, 1354 Schneider, 1994, Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer, J Nucl Med, 35, 1748 Sheikhbahaei, 2019, (18)F-NaF-PET/CT for the detection of bone metastasis in prostate cancer: A meta-analysis of diagnostic accuracy studies, Ann Nucl Med, 33, 351, 10.1007/s12149-019-01343-y Even-Sapir, 2006, The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT, J Nucl Med, 47, 287 Ohta, 2001, Whole body PET for the evaluation of bony metastases in patients with breast cancer: Comparison with 99Tcm-MDP bone scintigraphy, Nucl Med Commun, 22, 875, 10.1097/00006231-200108000-00005 Kato, 2005, Comparison between whole-body positron emission tomography and bone scintigraphy in evaluating bony metastases of esophageal carcinomas, Anticancer Res, 25, 4439 Shie, 2008, Meta-analysis: Comparison of F-18 Fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastases in patients with breast cancer, Clin Nucl Med, 33, 97, 10.1097/RLU.0b013e31815f23b7 Schirrmeister, 1999, Sensitivity in detecting osseous lesions depends on anatomic localization: Planar bone scintigraphy versus 18F PET, J Nucl Med, 40, 1623 Yang, 2002, Comparing whole body (18)F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphonate bone scan to detect bone metastases in patients with breast cancer, J Cancer Res Clin Oncol, 128, 325, 10.1007/s00432-002-0342-5 Wade, 2006, Flare response in 18F-fluoride ion PET bone scanning, AJR Am J Roentgenol, 186, 1783, 10.2214/AJR.05.0225 Shreve, 1996, Metastatic prostate cancer: Initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose, Radiology, 199, 751, 10.1148/radiology.199.3.8638000 Uematsu, 2005, Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer, AJR Am J Roentgenol, 184, 1266, 10.2214/ajr.184.4.01841266 Abe, 2005, Comparison of 18FDG-PET with 99mTc-HMDP scintigraphy for the detection of bone metastases in patients with breast cancer, Ann Nucl Med, 19, 573, 10.1007/BF02985050 Costelloe, 2010, FDG PET for the detection of bone metastases: Sensitivity, specificity and comparison with other imaging modalities, PET Clin, 5, 281, 10.1016/j.cpet.2010.04.001 Brown, 2020, Detecting the Undetectable, Clin Thyroidol, 32, 39, 10.1089/ct.2020;32.39-42 Parent, 2018, Update on (18)F-Fluciclovine PET for Prostate Cancer Imaging, J Nucl Med, 59, 733, 10.2967/jnumed.117.204032 Avrahami, 1989, Early MR demonstration of spinal metastases in patients with normal radiographs and CT and radionuclide bone scans, J Comput Assist Tomogr, 13, 598, 10.1097/00004728-198907000-00008 Tang, 2018, Multiparametric MR imaging of benign and malignant bone lesions, Magn Reson Imaging Clin N Am, 26, 559, 10.1016/j.mric.2018.06.010 Aisen, 1986, MRI and CT evaluation of primary bone and soft-tissue tumors, AJR Am J Roentgenol, 146, 749, 10.2214/ajr.146.4.749 Sarpel, 1987, Early diagnosis of spinal-epidural metastasis by magnetic resonance imaging, Cancer, 59, 1112, 10.1002/1097-0142(19870315)59:6<1112::AID-CNCR2820590612>3.0.CO;2-6 Godersky, 1987, Use of magnetic resonance imaging in the evaluation of metastatic spinal disease, Neurosurgery, 21, 676, 10.1227/00006123-198711000-00013 Robson, 2003, Magnetic resonance: An introduction to ultrashort TE (UTE) imaging, J Comput Assist Tomogr, 27, 825, 10.1097/00004728-200311000-00001 Breighner, 2019, Evaluation of osseous morphology of the hip using zero echo time magnetic resonance imaging, Am J Sports Med, 47, 3460, 10.1177/0363546519878170 van Vucht, 2019, The Dixon technique for MRI of the bone marrow, Skeletal Radiol, 48, 1861, 10.1007/s00256-019-03271-4 Ma, 2009, Fast dixon-based multisequence and multiplanar MRI for whole-body detection of cancer metastases, J Magn Reson Imaging, 29, 1154, 10.1002/jmri.21746 Hahn, 2018, Detection of vertebral metastases: A comparison between the modified Dixon turbo spin echo T2 weighted MRI and conventional T1 weighted MRI: A preliminary study in a tertiary centre, Br J Radiol, 91 Costelloe, 2013, Conspicuity of bone metastases on fast Dixon-based multisequence whole-body MRI: Clinical utility per sequence, Magn Reson Imaging, 31, 669, 10.1016/j.mri.2012.10.017 Messiou, 2019, Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: Myeloma response assessment and diagnosis system (MY-RADS), Radiology, 291, 5, 10.1148/radiol.2019181949 Padhani, 2017, METastasis reporting and data system for prostate cancer: Practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer, Eur Urol, 71, 81, 10.1016/j.eururo.2016.05.033 Stecco, 2018, Whole-body MRI with diffusion-weighted imaging in bone metastases: A narrative review, Diagnostics (Basel), 8 Eustace, 1997, A comparison of whole-body turboSTIR MR imaging and planar 99mTc-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases, AJR Am J Roentgenol, 169, 1655, 10.2214/ajr.169.6.9393186 Walker, 2000, Turbo STIR magnetic resonance imaging as a whole-body screening tool for metastases in patients with breast carcinoma: Preliminary clinical experience, J Magn Reson Imaging, 11, 343, 10.1002/(SICI)1522-2586(200004)11:4<343::AID-JMRI1>3.0.CO;2-P Lauenstein, 2002, Whole-body MRI using a rolling table platform for the detection of bone metastases, Eur Radiol, 12, 2091, 10.1007/s00330-002-1344-z Steinborn, 1999, Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system, J Comput Assist Tomogr, 23, 123, 10.1097/00004728-199901000-00026 Engelhard, 2004, Comparison of whole-body MRI with automatic moving table technique and bone scintigraphy for screening for bone metastases in patients with breast cancer, Eur Radiol, 14, 99, 10.1007/s00330-003-1968-7 Schmidt, 2007, Screening for bone metastases: Whole-body MRI using a 32-channel system versus dual-modality PET-CT, Eur Radiol, 17, 939, 10.1007/s00330-006-0361-8 Lauenstein, 2004, Whole-body MR imaging: Evaluation of patients for metastases, Radiology, 233, 139, 10.1148/radiol.2331030777 Antoch, 2003, Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology, JAMA, 290, 3199, 10.1001/jama.290.24.3199 Ohno, 2007, Whole-body MR imaging vs. FDG-PET: Comparison of accuracy of M-stage diagnosis for lung cancer patients, J Magn Reson Imaging, 26, 498, 10.1002/jmri.21031 Horvath, 1999, Total-body echo-planar MR imaging in the staging of breast cancer: Comparison with conventional methods–early experience, Radiology, 211, 119, 10.1148/radiology.211.1.r99ap33119 Costelloe, 2012, Fast Dixon whole-body MRI for detecting distant cancer metastasis: A preliminary clinical study, J Magn Reson Imaging, 35, 399, 10.1002/jmri.22815 Balliu, 2010, Comparative study of whole-body MRI and bone scintigraphy for the detection of bone metastases, Clin Radiol, 65, 989, 10.1016/j.crad.2010.07.002 Kalus, 2019, Whole-body MRI vs bone scintigraphy in the staging of Ewing sarcoma of bone: A 12-year single-institution review, Eur Radiol, 29, 5700, 10.1007/s00330-019-06132-9 Kim, 2019, Comparison of whole-body MRI, bone scan, and radiographic skeletal survey for lesion detection and risk stratification of Langerhans Cell Histiocytosis, Sci Rep, 9, 317, 10.1038/s41598-018-36501-1 Larkman, 2007, Parallel magnetic resonance imaging, Phys Med Biol, 52, R15, 10.1088/0031-9155/52/7/R01 Schlemmer, 2005, Fast whole-body assessment of metastatic disease using a novel magnetic resonance imaging system: Initial experiences, Invest Radiol, 40, 64, 10.1097/01.rli.0000149250.37033.7c Costelloe, 2007, Imaging characteristics of locally recurrent tumors of bone, AJR Am J Roentgenol, 188, 855, 10.2214/AJR.05.1132 Khodarahmi, 2019, Metal about the hip and artifact reduction techniques: From basic concepts to advanced imaging, Semin Musculoskelet Radiol, 23, e68, 10.1055/s-0039-1687898 Samarin, 2015, 18F-FDG-PET/MR increases diagnostic confidence in detection of bone metastases compared with 18F-FDG-PET/CT, Nucl Med Commun, 36, 1165, 10.1097/MNM.0000000000000387 Beiderwellen, 2014, Whole-body [(1)(8)F]FDG PET/MRI vs. PET/CT in the assessment of bone lesions in oncological patients: Initial results, Eur Radiol, 24, 2023, 10.1007/s00330-014-3229-3 Eisenhauer, 2009, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Clain, 1965, Secondary Malignant Disease of Bone, Br J Cancer, 19, 15, 10.1038/bjc.1965.3 Hayashi, 2013, A prospective study of bone tumor response assessment in metastatic breast cancer, Clin Breast Cancer, 13, 24, 10.1016/j.clbc.2012.09.004 Tsai, 2019, Prognostic and predictive factors for clinical and radiographic responses in patients with painful bone metastasis treated with magnetic resonance-guided focused ultrasound surgery, Int J Hyperthermia, 36, 932, 10.1080/02656736.2019.1655593 Yu, 2019, Treatment outcomes of stereotactic ablative radiation therapy for non-spinal bone metastases: Focus on response assessment and treatment indication, Br J Radiol, 92, 10.1259/bjr.20181048 Xu, 2016, Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma, J Clin Endocrinol Metab, 101, 4871, 10.1210/jc.2016-2815 Hortobagyi, 1996, Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group, N Engl J Med, 335, 1785, 10.1056/NEJM199612123352401 Hortobagyi, 1998, Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group, J Clin Oncol, 16, 2038, 10.1200/JCO.1998.16.6.2038 Theriault, 1999, Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group, J Clin Oncol, 17, 846, 10.1200/JCO.1999.17.3.846 Green, 1994, Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compound, J Bone Miner Res, 9, 745, 10.1002/jbmr.5650090521 Maxwell, 2003, Advances in supportive care of patients with cancer and bone metastases: Nursing implications of zoledronic acid, Clin J Oncol Nurs, 7, 403, 10.1188/03.CJON.403-408 Rosen, 2001, Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial, Cancer J, 7, 377 Rosen, 2003, Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial, Cancer, 98, 1735, 10.1002/cncr.11701 Van Poznak, 2017, Role of bone-modifying agents in metastatic breast cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused guideline update, J Clin Oncol, 35, 3978, 10.1200/JCO.2017.75.4614 Marx, 2003, Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic, J Oral Maxillofac Surg, 61, 1115, 10.1016/S0278-2391(03)00720-1 Aguiar Bujanda, 2007, Assessment of renal toxicity and osteonecrosis of the jaws in patients receiving zoledronic acid for bone metastasis, Ann Oncol, 18, 556, 10.1093/annonc/mdl408 Bamias, 2005, Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors, J Clin Oncol, 23, 8580, 10.1200/JCO.2005.02.8670 Dimopoulos, 2006, Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid, Haematologica, 91, 968 Durie, 2005, Osteonecrosis of the jaw and bisphosphonates, N Engl J Med, 353, 99, 10.1056/NEJM200507073530120 Ibrahim, 2008, Osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: A retrospective study, Oncologist, 13, 330, 10.1634/theoncologist.2007-0159 Maerevoet, 2005, Osteonecrosis of the jaw and bisphosphonates, N Engl J Med, 353, 99, 10.1056/NEJM200507073530120 Wang, 2007, Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy, J Oral Maxillofac Surg, 65, 1328, 10.1016/j.joms.2007.03.006 Zervas, 2006, Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: A single-centre experience in 303 patients, Br J Haematol, 134, 620, 10.1111/j.1365-2141.2006.06230.x Dimopoulos, 2009, Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid, Ann Oncol, 20, 117, 10.1093/annonc/mdn554 Ripamonti, 2009, Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan, Ann Oncol, 20, 137, 10.1093/annonc/mdn526 Farrugia, 2006, Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates, Laryngoscope, 116, 115, 10.1097/01.mlg.0000187398.51857.3c Saussez, 2009, Bisphosphonate-related osteonecrosis of the jaw and its associated risk factors: A Belgian case series, Laryngoscope, 119, 323, 10.1002/lary.20076 Fizazi, 2011, Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study, Lancet, 377, 813, 10.1016/S0140-6736(10)62344-6 Stopeck, 2010, Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study, J Clin Oncol, 28, 5132, 10.1200/JCO.2010.29.7101 Zunk, 1996, Phylogenetic relationships of Thlaspi s.l. (subtribe Thlaspidinae, Lepidieae) and allied genera based on chloroplast DNA restriction-site variation, Theor Appl Genet, 92, 375, 10.1007/BF00223682 Lipton, 2012, Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials, Eur J Cancer, 48, 3082, 10.1016/j.ejca.2012.08.002 Zheng, 2017, Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours, Eur J Cancer Care (Engl), 26, 10.1111/ecc.12541 Edwards, 2016, Incidence of atypical femur fractures in cancer patients: The MD Anderson Cancer Center Experience, J Bone Miner Res, 31, 1569, 10.1002/jbmr.2818 Lewington, 1991, A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone, Eur J Cancer, 27, 954, 10.1016/0277-5379(91)90257-E Sartor, 2004, Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer, Urology, 63, 940, 10.1016/j.urology.2004.01.034 Kasalicky, 1998, The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases, Eur J Nucl Med, 25, 1362, 10.1007/s002590050309 Robinson, 1989, Strontium-89: Treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone, Radiographics, 9, 271, 10.1148/radiographics.9.2.2467331 Pons, 1997, Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer, Eur J Nucl Med, 24, 1210, 10.1007/s002590050143 Baziotis, 1998, Strontium-89 chloride in the treatment of bone metastases from breast cancer, Oncology, 55, 377, 10.1159/000011881 Turner, 1991, A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate, Eur J Cancer, 27, 1084, 10.1016/0277-5379(91)90297-Q Alberts, 1997, Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone, Radiother Oncol, 43, 175, 10.1016/S0167-8140(97)01912-9 Lam, 2007, Bone seeking radiopharmaceuticals for palliation of pain in cancer patients with osseous metastases, Anticancer Agents Med Chem, 7, 381, 10.2174/187152007781058596 Farhanghi, 1992, Samarium-153-EDTMP: Pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer, J Nucl Med, 33, 1451 Serafini, 2001, Therapy of metastatic bone pain, J Nucl Med, 42, 895 Goeckeler, 1993, Analysis of urine samples from metastatic bone cancer patients administered 153Sm-EDTMP, Nucl Med Biol, 20, 657, 10.1016/0969-8051(93)90036-T Paszkowski, 1999, Disseminated intravascular coagulation in a patient treated with strontium-89 for metastatic carcinoma of the prostate, Clin Nucl Med, 24, 852, 10.1097/00003072-199911000-00006 Bruland, 2006, High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: Adjuvant or alternative to conventional modalities?, Clin Cancer Res, 12, 6250s, 10.1158/1078-0432.CCR-06-0841 Parker, 2013, Alpha emitter radium-223 and survival in metastatic prostate cancer, N Engl J Med, 369, 213, 10.1056/NEJMoa1213755 Nilsson, 2016, Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study, Ann Oncol, 27, 868, 10.1093/annonc/mdw065 Ueno, 2020, Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer, Cancer Med, 9, 1025, 10.1002/cam4.2780 Smith, 2019, Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): A randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, 20, 408, 10.1016/S1470-2045(18)30860-X Sartor, 2017, Re-treatment with radium-223: First experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases, Ann Oncol, 28, 2464, 10.1093/annonc/mdx331 Hartsell, 2005, Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases, J Natl Cancer Inst, 97, 798, 10.1093/jnci/dji139 McQuay, 2000, Radiotherapy for the palliation of painful bone metastases, Cochrane Database Syst Rev Lutz, 2017, Palliative radiation therapy for bone metastases: Update of an ASTRO evidence-based guideline, Pract Radiat Oncol, 7, 4, 10.1016/j.prro.2016.08.001 Spencer, 2019, Systematic Review of the Role of Stereotactic Radiotherapy for Bone Metastases, J Natl Cancer Inst, 111, 1023, 10.1093/jnci/djz101 Jhaveri, 2008, Stereotactic body radiotherapy in the management of painful bone metastases, Oncology (Williston Park), 22, 782 Sprave, 2018, Randomized phase II trial evaluating pain response in patients with spinal metastases following stereotactic body radiotherapy versus three-dimensional conformal radiotherapy, Radiother Oncol, 128, 274, 10.1016/j.radonc.2018.04.030 McGee, 2019, Analysis of Local Control and Pain Control After Spine Stereotactic Radiosurgery Reveals Inferior Outcomes for Hepatocellular Carcinoma Compared With Other Radioresistant Histologies, Pract Radiat Oncol, 9, 89, 10.1016/j.prro.2018.11.009 Palma, 2019, Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): Study protocol for a randomized phase III trial, BMC Cancer, 19, 816, 10.1186/s12885-019-5977-6 Patchell, 2005, Direct decompressive surgical resection in the treatment of spinal cord compression caused by metastatic cancer: A randomised trial, Lancet, 366, 643, 10.1016/S0140-6736(05)66954-1 Aboulafia, 2007, Surgical therapy of bone metastases, Semin Oncol, 34, 206, 10.1053/j.seminoncol.2007.03.002 Beals, 1971, Prophylactic internal fixation of the femur in metastatic breast cancer, Cancer, 28, 1350, 10.1002/1097-0142(1971)28:5<1350::AID-CNCR2820280539>3.0.CO;2-6 Fidler, 1973, Prophylactic internal fixation of secondary neoplastic deposits in long bones, Br Med J, 1, 341, 10.1136/bmj.1.5849.341 Fidler, 1981, Incidence of fracture through metastases in long bones, Acta Orthop Scand, 52, 623, 10.3109/17453678108992157 Mirels, 1989, Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures, Clin Orthop Relat Res, 256 Nazarian, 2015, Treatment Planning and Fracture Prediction in Patients with Skeletal Metastasis with CT-Based Rigidity Analysis, Clin Cancer Res, 21, 2514, 10.1158/1078-0432.CCR-14-2668 Voggenreiter, 2005, Balloon kyphoplasty is effective in deformity correction of osteoporotic vertebral compression fractures, Spine (Phila Pa 1976), 30, 2806, 10.1097/01.brs.0000190885.85675.a0 Lee, 2009, The efficacy of percutaneous vertebroplasty for vertebral metastases associated with solid malignancies, Eur J Cancer, 45, 1597, 10.1016/j.ejca.2009.01.021 Mendel, 2009, Percutaneous techniques in the treatment of spine tumors: What are the diagnostic and therapeutic indications and outcomes?, Spine (Phila Pa 1976), 34, S93, 10.1097/BRS.0b013e3181b77895 Goetz, 2004, Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: A multicenter study, J Clin Oncol, 22, 300, 10.1200/JCO.2004.03.097 Dupuy, 2010, Percutaneous radiofrequency ablation of painful osseous metastases: A multicenter American College of Radiology Imaging Network trial, Cancer, 116, 989, 10.1002/cncr.24837 Prologo, 2014, Image-guided cryoablation for the treatment of painful musculoskeletal metastatic disease: A single-center experience, Skeletal Radiol, 43, 1551, 10.1007/s00256-014-1939-x McArthur, 2017, Percutane image-guided cryoablation of painful osseous metastases: A retrospective single-center review, Curr Probl Diagn Radiol, 46, 282, 10.1067/j.cpradiol.2016.11.007 Umer, 2018, Skeletal metastasis in renal cell carcinoma: A review, Ann Med Surg (Lond), 27, 9, 10.1016/j.amsu.2018.01.002 Lin, 2007, Patient survival after surgery for osseous metastases from renal cell carcinoma, J Bone Joint Surg Am, 89, 1794, 10.2106/00004623-200708000-00018